Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5 HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response - Hesketh, P J; Grunberg, S M; Herrstedt, J; de Wit, R; Gralla, R J; Carides, A D; Taylor, A; Evans, J K; Horgan, K J (Support Care Cancer, 2006)